Euploid Biotechnologies

Overview

Euploid Biotechnologies is a European fertility-biotechnology startup described in the episode as developing Liventa, an experimental molecule intended to protect chromosome cohesion during egg maturation.

Current Profile

The reported approach is indirect. Rather than imitate shugoshin-1, Liventa is said to occupy the enzyme that would otherwise degrade this chromosome-protecting molecule. The intended downstream result is fewer segregation errors and more chromosomally normal eggs available during IVF.

The profile remains preclinical. The supplied summary says the startup had not reached clinical trials and does not provide primary research, leadership, regulatory, financing, or outcome records.

Key Characteristics

• European startup focused on chromosomally normal eggs for IVF.
• Developer of the reported Liventa molecule.
• Uses an enzyme-diversion rather than direct-protection strategy.
• Targets the preservation of shugoshin-1 activity during egg maturation.
• Remains preclinical in the supplied episode summary.

Evidence

• Program identity - Fertile ambitions names Euploid Biotechnologies and Liventa.
• Mechanism - Fertile ambitions says Liventa keeps the shugoshin-degrading enzyme occupied elsewhere.
• Development boundary - Fertile ambitions says the discussed startups had not entered clinical trials.

Qualifications

This profile rests on one structured podcast summary rather than company materials, peer-reviewed research, trial records, or regulatory filings. The wiki does not independently verify the target enzyme, molecular design, selectivity, development stage, safety, or efficacy. Company and product claims remain episode-scoped.

What Changed

• Established Euploid Biotechnologies as the enzyme-diversion branch of experimental egg chromosome stabilization.
• Recorded its preclinical status as a defining qualification.

Relationships

• Oocyte Chromosome Stabilization - experimental pathway the company is pursuing.
• OvaLabs - startup pursuing a direct-protection strategy on the same reported pathway.
• Ovarian Reserve and AMH Interpretation - adjacent quantity-versus-quality framework.
• Assisted Reproduction Decision Literacy - IVF decision context in which any validated treatment would operate.